What Do FVC and DLCO Mean in Sarcoidosis PFTs?
At a Glance
In sarcoidosis breathing tests, FVC measures how much air your lungs can hold, and DLCO measures how well they transfer oxygen to your blood. A drop of 10% in FVC or 15% in DLCO is a key warning sign of lung inflammation or scarring that may require a change in treatment.
In this answer
4 sections
When you have pulmonary sarcoidosis, breathing tests—specifically pulmonary function tests (PFTs)—are a critical part of your routine care. Your doctor looks closely at two specific numbers: your FVC and your DLCO. Simply put, FVC measures how much air your lungs can hold, and DLCO measures how well your lungs transfer oxygen into your blood [1]. Because sarcoidosis can cause inflammation or scarring in the lungs, doctors track these percentages over time [2]. A significant drop in these numbers between visits is a key indicator of disease progression, signaling that it may be time to investigate further or adjust your treatment [3][4].
Depending on how active your sarcoidosis is, you can expect to repeat these PFTs every 3 to 6 months, or annually if your condition is stable. Tip: Try to have your PFTs done at the same pulmonary lab each time, as different machines and calibrations can cause slight variations in your results.
What is FVC (Forced Vital Capacity)?
FVC stands for Forced Vital Capacity. It measures the total amount of air you can forcefully blow out of your lungs after taking the deepest breath possible.
Think of FVC as a measurement of your lung size or volume. When sarcoidosis causes inflammation (granulomas) or permanent scarring (fibrosis) in the lung tissue, the lungs can become stiff [5]. Stiff lungs cannot expand fully to take in as much air, which causes your FVC percentage to go down. FVC is widely considered the most accurate single measurement for tracking how sarcoidosis is affecting your lungs over time [1][6].
What is DLCO (Diffusing Capacity)?
DLCO stands for Diffusing Capacity of the Lungs for Carbon Monoxide. While it sounds complicated, it simply measures how efficiently your lungs transfer oxygen from the air you breathe into your bloodstream.
Even if your lungs can hold a normal amount of air (a normal FVC), inflammation or scarring from sarcoidosis can thicken the delicate membranes where oxygen enters the blood. If these membranes are thick or damaged, your DLCO percentage will drop [7]. It is also important to know that temporary issues, like anemia (low hemoglobin), can artificially lower your DLCO score, which is why your doctor will often look at routine bloodwork alongside your breathing tests.
If your FVC is normal but your DLCO drops significantly, this can be an early warning sign of pulmonary hypertension (high blood pressure in the blood vessels of the lungs), a known complication of sarcoidosis [8][9].
Why Doctors Watch for a 10% to 15% Drop
Doctors do not just look at a single PFT result in isolation; they look at the trend over months or years. Your results are given as a “percent predicted,” comparing your numbers to what is expected for someone of your age, height, sex, and ethnicity.
When looking for disease progression, pulmonologists look for an absolute drop in your percent predicted points [3]. For example, if your FVC was 80% predicted last time and is 70% predicted this time, that is a 10-point (or 10%) absolute drop.
- For FVC: A drop of 10% or more (10 points) is considered a clinically significant sign of decline.
- For DLCO: Because this test naturally fluctuates more from day to day, doctors typically look for a drop of 15% or more (15 points) to definitively confirm progression, though they will closely watch any downward trend.
A significant decline may indicate:
- Active Inflammation: Your sarcoidosis may be flaring up.
- Disease Progression: Granulomas may be causing permanent scarring, known as pulmonary fibrosis [5][10].
- Need for Treatment Adjustment: Your current medications may not be controlling the disease effectively [4].
- Other Complications: A drop in DLCO might prompt your doctor to screen for pulmonary hypertension with an echocardiogram [11][12].
Conversely, an increase in your FVC of more than 5% (5 points) is often viewed as a reliable sign that your therapy is working [2].
Will I Feel This Drop?
Not always. The reason PFTs are so important is that they can detect lung decline before you feel it in your daily life. Sometimes a 10% drop will cause you to feel noticeably more short of breath or fatigued when climbing stairs, but for others, it happens silently. If you do suddenly feel more breathless or experience a new cough, contact your doctor immediately, even if your next breathing test isn’t scheduled for months.
Next Steps When Your Numbers Drop
If your numbers have dropped significantly, your doctor will likely want to look deeper. They may order a High-Resolution CT (HRCT) scan or a PET scan to see if the decline is caused by active inflammation (which can often be treated) or irreversible scarring [13][5]. This helps you and your care team make informed decisions about whether to start, increase, or change your immunosuppressive therapy.
Common questions in this guide
What does FVC measure in sarcoidosis?
What does DLCO mean on my breathing test?
Why does my doctor look for a 10% drop in my PFT numbers?
Can a low DLCO indicate other sarcoidosis complications?
Does anemia affect my DLCO results?
Questions to Ask Your Doctor
Curated prompts to bring to your next appointment.
- 1.What are my current baseline 'percent predicted' numbers for FVC and DLCO?
- 2.Are you seeing any concerning trends in my DLCO or FVC between this visit and my last?
- 3.If my DLCO is significantly lower than my FVC, is there a risk of pulmonary hypertension, and should I have an echocardiogram?
- 4.Was my DLCO score adjusted for my current hemoglobin levels to account for potential anemia?
- 5.If I feel sudden shortness of breath before my next scheduled PFT, how quickly should I contact the office for an early evaluation?
Questions For You
Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.
Related questions
References
References (13)
- 1
Pulmonary Sarcoidosis.
Valeyre D, Bernaudin JF, Jeny F, et al.
Clinics in chest medicine 2015; (36(4)):631-41.
PMID: 26593138 - 2
Pulmonary Function in Pulmonary Sarcoidosis.
Yao Q, Ji Q, Zhou Y
Journal of clinical medicine 2023; (12(21)) doi:10.3390/jcm12216701.
PMID: 37959167 - 3
Treatment of Granulomatous Inflammation in Pulmonary Sarcoidosis.
Gerke AK
Journal of clinical medicine 2024; (13(3)) doi:10.3390/jcm13030738.
PMID: 38337432 - 4
Validation of Proposed Criteria for Progressive Pulmonary Fibrosis.
Pugashetti JV, Adegunsoye A, Wu Z, et al.
American journal of respiratory and critical care medicine 2023; (207(1)):69-76 doi:10.1164/rccm.202201-0124OC.
PMID: 35943866 - 5
High-Resolution CT Scan Fibrotic Patterns in Stage IV Pulmonary Sarcoidosis: Impact on Pulmonary Function and Survival.
Obi ON, Alqalyoobi S, Maddipati V, et al.
Chest 2024; (165(4)):892-907 doi:10.1016/j.chest.2023.10.021.
PMID: 37879560 - 6
[Dynamics of clinical, X-ray and functional data during treatment of patients with sarcoidosis].
Vizel IY, Vizel AA
Klinicheskaia meditsina 2017; (95(1)):60-5.
PMID: 30299068 - 7
Relationship between radiologic patterns, pulmonary function values and bronchoalveolar lavage fluid cells in newly diagnosed sarcoidosis.
Aleksonienė R, Zeleckienė I, Matačiūnas M, et al.
Journal of thoracic disease 2017; (9(1)):88-95 doi:10.21037/jtd.2017.01.17.
PMID: 28203410 - 8
Predictive value of pulmonary function testing in the evaluation of pulmonary hypertension in sarcoidosis.
Jose A, Delio J, Gwizdala J, et al.
Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG 2018; (35(4)):308-316 doi:10.36141/svdld.v35i4.6855.
PMID: 32476918 - 9
Physical Functioning and Symptoms of Chronic Fatigue in Sarcoidosis Patients.
Pilzak K, Żebrowska A, Sikora M, et al.
Advances in experimental medicine and biology 2018; (1040()):13-21 doi:10.1007/5584_2017_85.
PMID: 29067627 - 10
Four-year survival rate in pulmonary sarcoidosis with extensive pulmonary hypertension screening.
Huitema MP, Mathijssen H, Bakker ALM, et al.
Respiratory medicine 2022; (195()):106762 doi:10.1016/j.rmed.2022.106762.
PMID: 35227546 - 11
Systemic sarcoidosis revealed by venepunctures: a very rare but rewarding cutaneous manifestation.
Killian M, Habougit C, Monard E, Gramont B
BMJ case reports 2020; (13(9)) doi:10.1136/bcr-2020-235784.
PMID: 32900730 - 12
Diffusing Capacity of the Lungs for Carbon Monoxide and Echocardiographic Parameters in Identifying Mild Pulmonary Hypertension in the EUSTAR Cohort of Patients With Systemic Sclerosis.
Colalillo A, Hachulla E, Pellicano C, et al.
Chest 2024; (166(4)):837-844 doi:10.1016/j.chest.2024.05.010.
PMID: 38849072 - 13
Meta-analysis of [18F]FDG-PET/CT in pulmonary sarcoidosis.
Donnelly R, McDermott M, McManus G, et al.
European radiology 2025; (35(4)):2222-2232 doi:10.1007/s00330-024-10949-4.
PMID: 39044038
This page explains pulmonary function test terminology for educational purposes. Your pulmonologist is the best source for interpreting your specific PFT results and sarcoidosis progression.
Get notified when new evidence is published on Sarcoidosis.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.